BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...
Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...
The Brighterside of News on MSN18d
New CAR-T therapy achieved complete remission in 70% of aggressive cancer patientsCAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with remission rates reaching as high as 90%. This therapy modifies a patient’s T ...
Century Therapeutics, Inc. (NASDAQ: IPSC) outlined a strategic pipeline re-prioritization and shared its financial results ...
Less than 18 months after listing on the Nasdaq, CAR-T therapy developer CARGO Therapeutics has abandoned its development ...
CEO Gina Chapman is also departing the company, which plans to review options for pursuing a reverse merger or other business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback